Oligodendroglioma Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

PRESS RELEASE
Published March 14, 2023

Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, Oligodendroglioma pipeline constitutes 10+ key companies continuously working towards developing 10+ Oligodendroglioma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Oligodendroglioma Overview
Oligodendroglioma (OG) develop from glial cells called oligodendrocytes. These cells make a fatty white substance (myelin) that covers the nerves. Myelin helps signals (impulses) to travel along the nerves more quickly. Oligodendrogliomas are mostly found in the frontal lobe of the cerebrum.

Oligodendroglioma Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Oligodendroglioma Market.

The Oligodendroglioma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Oligodendroglioma Pipeline Report:
• Companies across the globe are diligently working toward developing novel Oligodendroglioma treatment therapies with a considerable amount of success over the years. Oligodendroglioma Key players such as – Xynomic Pharmaceuticals, Inc., Oblato, Inc., SpringWorks Therapeutics, Incyte Corporation, and others, are developing therapies for the Oligodendroglioma treatment
• Oligodendroglioma Emerging therapies such as – PCI-24781, OKN-007, Mirdametinib, Pemigatinib, Retifanlimab, and others are expected to have a significant impact on the Oligodendroglioma market in the coming years.
• In June 2021, Spring Works Therapeutics, Inc. initiated a Phase I/II open-label, multi-center study of the brain-penetrant MEK inhibitor, mirdametinib (PD-0325901), in patients with pediatric low-grade glioma (pLGG)

Route of Administration
Oligodendroglioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Intravenous
• Subcutaneous

Molecule Type
Products have been categorized under various Molecule types, such as
• Gene Therapy
• Small molecule
• Antibody

Oligodendroglioma Pipeline Therapeutics Assessment
• Oligodendroglioma Assessment by Product Type
• Oligodendroglioma By Stage and Product Type
• Oligodendroglioma Assessment by Route of Administration
• Oligodendroglioma By Stage and Route of Administration
• Oligodendroglioma Assessment by Molecule Type
• Oligodendroglioma by Stage and Molecule Type

DelveInsight’s Oligodendroglioma Report covers around 10+ products under different phases of clinical development like-
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of the key companies in the Oligodendroglioma Therapeutics Market include:
Key companies developing therapies for Oligodendroglioma are – AngioChem Inc., Axelar AB, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cavion LLC, Celldex Therapeutics, Inc., F. Hoffmann-La Roche Ltd., Millennium Pharmaceuticals Inc, Novartis AG, Pfizer Inc., Tocagen Inc., and others.

Emerging Oligodendroglioma Drugs Under Different Phases of Clinical Development Include:
• PCI-24781: Xynomic Pharmaceuticals, Inc.
• OKN-007: Oblato, Inc.
• ONC201: Chimerix
• RRx-001: EpicentRx
• Mirdametinib: SpringWorks Therapeutics
• Pemigatinib: Incyte Corporation
• Retifanlimab: Incyte Corporation

Get a Free Sample PDF Report to know more about Oligodendroglioma Pipeline Therapeutic Assessment

Oligodendroglioma Pipeline Analysis:
The Oligodendroglioma pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Oligodendroglioma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Oligodendroglioma Treatment.
• Oligodendroglioma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Oligodendroglioma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Oligodendroglioma market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Oligodendroglioma product details are provided in the report. Download the Oligodendroglioma pipeline report to learn more about the emerging Oligodendroglioma therapies

Oligodendroglioma Pipeline Market Drivers
• Rising incidence of the Oligodendroglioma
• Advancements in pharmacology and molecular biology to promote drug development

Oligodendroglioma Pipeline Market Barriers
• High cost associated with the management
• Side effects associated with the treatment

Scope of Oligodendroglioma Pipeline Drug Insight
• Coverage: Global
• Key Oligodendroglioma Companies: Xynomic Pharmaceuticals, Inc., Oblato, Inc., SpringWorks Therapeutics, Incyte Corporation, and others
• Key Oligodendroglioma Therapies: PCI-24781, OKN-007, Mirdametinib, Pemigatinib, Retifanlimab, and others
• Oligodendroglioma Therapeutic Assessment: Oligodendroglioma current marketed and Oligodendroglioma emerging therapies
• Oligodendroglioma Market Dynamics: Oligodendroglioma market drivers and Oligodendroglioma market barriers

Request for Sample PDF Report for Oligodendroglioma Pipeline Assessment and clinical trials

Table of Contents
1 Oligodendroglioma Report Introduction
2 Oligodendroglioma Executive Summary
3 Oligodendroglioma Overview
4 Oligodendroglioma- Analytical Perspective In-depth Commercial Assessment
5 Oligodendroglioma Pipeline Therapeutics
6 Oligodendroglioma Late Stage Products (Phase II/III)
7 Oligodendroglioma Mid Stage Products (Phase II)
8 Oligodendroglioma Early Stage Products (Phase I)
9 Oligodendroglioma Preclinical Stage Products
10 Oligodendroglioma Therapeutics Assessment
11 Oligodendroglioma Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Oligodendroglioma Key Companies
14 Oligodendroglioma Key Products
15 Oligodendroglioma Unmet Needs
16 Oligodendroglioma Market Drivers and Barriers
17 Oligodendroglioma Future Perspectives and Conclusion
18 Oligodendroglioma Analyst Views
19 Appendix
20 About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about Oligodendroglioma drugs and therapies

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com/consulting

 

Newsmantraa